Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study

Documenti analoghi

• Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation
  di: Moazzam Shahzad, et al.
  Pubblicazione: (2024)
• Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
  di: Danai Dima, et al.
  Pubblicazione: (2024)
• Early Childhood STEAM: Reflections from a Year of STEAM Initiatives Implemented in a High-Needs Primary School
  di: DeJarnette, Nancy K.
  Pubblicazione: (2018)
• Parkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel
  di: Audrey Couturier, et al.
  Pubblicazione: (2024)
• Brown representability for directed graphs
  di: McGuirk, Zachary, et al.
  Pubblicazione: (2020)